Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Phase 2 Terminated 13 enrolled Vanderbilt-Ingram Cancer Center National Cancer Institute (NCI) · collab National Comprehensive Cancer Network · collab

NaSingle-groupOpen-labelOther

Summary

This phase II trial studies how well giving dabrafenib alone and in combination with trametinib before surgery works in treating patients with advanced melanoma that can be removed by surgery. Studying samples of tumor tissue in the laboratory from patients receiving dabrafenib and trametinib may help doctors learn more about the effects of these drugs on cells and help identify biomarkers that determine which patients will respond to these drugs best.

Timeline

Start: 2013-01
Primary completion: 2015-02
Completion: 2015-04

Publications

Results Johnson AS, Crandall H, Dahlman K, Kelley MC. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma. J Am Coll Surg. 2015 Apr;220(4):581-93.e1. doi: 10.1016/j.jamcollsurg.2014.12.057. Epub 2015 Jan 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dabrafenib	Small molecule	150 mg	Oral
Subject	Trametinib	Small molecule	2 mg	Oral

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Summary

Timeline

Publications

Drugs

Indications